Financials Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-04-12 EDT 5-day change 1st Jan Change
68.07 USD -0.84% Intraday chart for Gilead Sciences, Inc. -2.17% -15.97%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 82,209 73,031 91,081 107,677 100,942 84,881 - -
Enterprise Value (EV) 1 82,450 103,910 118,530 126,522 118,665 97,684 91,338 85,731
P/E ratio 15.4 x 583 x 14.7 x 23.6 x 18 x 13.5 x 12.3 x 11.5 x
Yield 3.88% 4.67% 3.91% 3.4% 3.7% 4.61% 4.81% 4.87%
Capitalization / Revenue 3.66 x 2.96 x 3.34 x 3.95 x 3.72 x 3.08 x 3.03 x 2.96 x
EV / Revenue 3.67 x 4.21 x 4.34 x 4.64 x 4.38 x 3.55 x 3.27 x 2.99 x
EV / EBITDA 6.61 x 7.88 x 8.12 x 8.86 x 9.01 x 7.38 x 6.44 x 5.95 x
EV / FCF 9.91 x 13.8 x 11 x 15.2 x 16 x 11 x 9.76 x 8.72 x
FCF Yield 10.1% 7.24% 9.12% 6.59% 6.25% 9.08% 10.3% 11.5%
Price to Book 3.65 x 4.04 x 4.32 x 5.05 x 4.48 x 3.48 x 3.12 x 2.81 x
Nbr of stocks (in thousands) 1,265,146 1,253,528 1,254,384 1,254,244 1,246,042 1,246,969 - -
Reference price 2 64.98 58.26 72.61 85.85 81.01 68.07 68.07 68.07
Announcement Date 20-02-04 21-02-04 22-02-01 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,449 24,689 27,305 27,281 27,116 27,516 27,968 28,696
EBITDA 1 12,468 13,184 14,598 14,283 13,177 13,244 14,176 14,397
EBIT 1 11,064 11,704 12,548 12,180 10,484 10,761 11,806 12,160
Operating Margin 49.29% 47.41% 45.95% 44.65% 38.66% 39.11% 42.21% 42.38%
Earnings before Tax (EBT) 1 5,160 1,669 8,278 5,814 6,859 8,239 8,638 8,974
Net income 1 5,386 123 6,225 4,592 5,665 6,536 6,858 7,313
Net margin 23.99% 0.5% 22.8% 16.83% 20.89% 23.75% 24.52% 25.48%
EPS 2 4.220 0.1000 4.930 3.640 4.500 5.037 5.542 5.906
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,874 9,362 9,827
FCF margin 37.06% 30.45% 39.57% 30.59% 27.37% 32.25% 33.48% 34.25%
FCF Conversion (EBITDA) 66.72% 57.02% 74.02% 58.42% 56.32% 67.01% 66.05% 68.26%
FCF Conversion (Net income) 154.46% 6,112.2% 173.57% 181.71% 131% 135.78% 136.52% 134.38%
Dividend per Share 2 2.520 2.720 2.840 2.920 3.000 3.138 3.273 3.312
Announcement Date 20-02-04 21-02-04 22-02-01 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 7,421 7,244 6,590 6,260 7,042 7,389 6,352 6,599 7,051 7,115 6,358 6,787 7,062 7,317 6,660
EBITDA 1 4,902 2,042 4,049 3,195 3,811 3,227 2,883 3,258 3,908 3,427 3,287 3,352 3,710 3,580 -
EBIT 1 4,379 1,507 3,524 2,670 3,286 2,699 2,243 2,277 3,224 2,739 1,827 2,813 3,106 2,968 2,803
Operating Margin 59.01% 20.8% 53.47% 42.65% 46.66% 36.53% 35.31% 34.51% 45.72% 38.5% 28.73% 41.45% 43.99% 40.56% 42.08%
Earnings before Tax (EBT) 1 3,438 759 -152 1,503 2,432 2,031 1,300 1,588 2,318 1,653 1,911 1,946 2,332 2,256 2,122
Net income 1 2,592 382 19 1,144 1,789 1,640 1,010 1,045 2,180 1,429 1,434 1,498 1,862 1,841 1,663
Net margin 34.93% 5.27% 0.29% 18.27% 25.4% 22.2% 15.9% 15.84% 30.92% 20.08% 22.55% 22.08% 26.36% 25.17% 24.97%
EPS 2 2.050 0.3000 0.0200 0.9100 1.420 1.300 0.8000 0.8300 1.730 1.140 0.8445 1.250 1.501 1.395 1.315
Dividend per Share 2 0.7100 0.7100 0.7300 0.7300 0.7300 0.7300 0.7500 0.7500 0.7500 0.7500 0.7600 0.7600 0.7600 0.7600 0.7500
Announcement Date 21-10-28 22-02-01 22-04-28 22-08-02 22-10-27 23-02-02 23-04-27 23-08-03 23-11-07 24-02-06 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 241 30,879 27,449 18,845 17,723 12,803 6,457 850
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.0193 x 2.342 x 1.88 x 1.319 x 1.345 x 0.9667 x 0.4555 x 0.059 x
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,875 9,362 9,827
ROE (net income / shareholders' equity) 38.3% 43.8% 46.8% 43.3% 38.5% 26.8% 35.4% 32.1%
ROA (Net income/ Total Assets) 8.6% 0.19% 9.13% 14% 13.5% 7.86% 12.3% 12.2%
Assets 1 62,651 65,079 68,180 32,874 41,980 83,183 55,879 59,776
Book Value Per Share 2 17.80 14.40 16.80 17.00 18.10 19.60 21.80 24.20
Cash Flow per Share 2 7.160 6.470 9.020 7.190 6.360 6.600 7.720 8.600
Capex 1 825 650 579 728 585 671 716 722
Capex / Sales 3.67% 2.63% 2.12% 2.67% 2.16% 2.44% 2.56% 2.51%
Announcement Date 20-02-04 21-02-04 22-02-01 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.07 USD
Average target price
86.37 USD
Spread / Average Target
+26.89%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Financials Gilead Sciences, Inc.